Pure Global
NCT06042855

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Susanna Naggie, MD·Phase 3·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Covid19
Drug/Device/Intervention
Placebo
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Susanna Naggie, MD
Funder
Duke University
Location
Chandler,Gilbert,Mesa,Peoria,Little Rock,Newport Beach,North Hollywood,Palo Alto,Sylmar,Colorado Springs,Colorado Springs,Stamford,Washington,Deerfield Beach,Gainesville,Gainesville,Hialeah,Jacksonvil, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Sep 05, 2023
End date
Mar 01, 2024
Enrollment
15000 participants
Primary outcome

Time to sustained recovery in Days,Number of Participants With Hospitalization or Death

Summary

The purpose of this study is to evaluate the effectiveness of repurposed medications (study
 drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
 Participants will receive either study drug or placebo. Participants will self-report any new
 or worsening symptoms or medical events experienced while taking study drug or placebo. This
 study is intended to be all remote with no in person visits, unless the study team feels it
 is in the best interest of a participant to be seen in person.
 
 Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the
 activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov
 entry and will include Pro00107921 in the Unique Protocol ID.

ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteRift Valley feverPlague
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06042855
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06042855 through Pure Global AI's free database. This Phase 3 trial is sponsored by Susanna Naggie, MD and is currently Recruiting. The study focuses on Covid19. Target enrollment is 15000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.